New vaccine could fight deadly lassa fever – first human trial underway
NCT ID NCT06546709
Summary
This study tests a new vaccine to prevent Lassa fever, a serious viral illness. About 55 healthy adults will receive two doses of the vaccine to see if it is safe and triggers an immune response. The vaccine uses a modified rabies virus to deliver the Lassa antigen, and may also protect against rabies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LASSA FEVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.